ELTX elicio.com: Multiplikator nilai perusahaan marang pendapatan

elicio.com (ELTX) - logo korporat

Elicio Therapeutics (ELTX) lacks regular revenue streams, as vaccine development depends on grants and test results. Manufacturing processes and research are fully outsourced to external contractors. The patent-protected AMP platform ensures business sustainability. The enterprise value-to-annual revenue multiple reflects the valuation trend, with the value stabilizing at 0.00.

ELTX: Multiplikator EV/Sales Elicio Therapeutics, Inc. 23.11.2025 - 20.11.2026

elicio.com - rincian analitis lan metrik utama (ELTX)

- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi saham perusahaan:
- indikator dhuwit lan arus kas:
Analisis wiwitan perusahaan:Elicio Therapeutics - ELTX
Produk asli Elicio Therapeutics

Elicio Therapeutics (ELTX) is currently in the cancer vaccine development stage, where laboratory research costs outweigh revenues. The EV/Revenue multiple visualizes the total enterprise value, including net debt, relative to sales volume. This metric determines the market revaluation of assets while excluding the influence of the financing structure. For a startup lacking operating leverage, this indicator serves as a marker of speculative demand. Exceeding historical averages signals a potential overheating of the stock.